

24 April 2012
EMA/47793/2012
Human Medicines Development and Evaluation

EMA workshop on Pharmacogenomics: from science to clinical care

Invitation for expressions of interest: PGWPSecretariat@ema.europa.eu.

The European Medicines Agency is hosting a two-day workshop on pharmacogenomics impact on public health and opportunities for new treatment models based on prediction and prevention.

The workshop will be held on the 8th and 9th October 2012 at the EMA in London, UK.

Objectives of the planned workshop

1. Share international expert views on pharmacogenomic applications in clinical development, approval and patient's access to medicines
2. Discuss challenges and bottlenecks
3. Identify areas for regulators and other stakeholders' joint actions

Sessions

The sessions will be designed around 6-8 controversial topics. Each session consists of two 15 min. presentations from stakeholders followed by 20 min. discussion:

- Pharmacogenomics: regulatory and methodological implications in early clinical development
- Adaptive designs and enrichment strategies for confirmatory clinical trials
- Post-approval pharmacogenomics: impact on Risk Management Plans and Information
- Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs)
- Pharmacogenomics: impact and needs from health care view point to facilitate patients' access
- Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity

Expressions of interest

Although speakers will be by invitation and capacity will be limited, we invite interested experts and stakeholders to send an expression of interest to attend this workshop by 15 June 2012 to PGWPSecretariat@ema.europa.eu.